MOTRIN MIGRAINE PAIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MOTRIN MIGRAINE PAIN (MOTRIN MIGRAINE PAIN).
Reversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby alleviating pain and inflammation.
| Metabolism | Primarily hepatic via CYP2C9; metabolites undergo glucuronidation and renal excretion. |
| Excretion | Renal: 90% (metabolites and unchanged, 10-20% unchanged). Biliary/Fecal: <5%. |
| Half-life | 2 hours (1.5-2.5 h in adults; prolonged in elderly and renal impairment). |
| Protein binding | 99% bound to albumin. |
| Volume of Distribution | 0.1-0.2 L/kg. Clinical meaning: Low Vd indicates limited tissue distribution, primarily in plasma. |
| Bioavailability | Oral: 80-100% (absolute bioavailability). |
| Onset of Action | Oral: 30-60 minutes for analgesia. Peak effect: 1-2 hours. |
| Duration of Action | 4-6 hours (oral). Clinical note: Duration is dose-dependent; higher doses may provide longer relief. |
| Molecular Weight | 206.28 |
Ibuprofen 400 mg orally every 4-6 hours as needed, maximum 1200 mg in 24 hours.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-59 mL/min: No adjustment; eGFR 15-29 mL/min: Reduce dose to 200 mg every 6-8 hours, maximum 600 mg/day; eGFR <15 mL/min: Avoid use. |
| Liver impairment | Child-Pugh Class A: No adjustment; Child-Pugh Class B: Use with caution, reduce dose by 50%; Child-Pugh Class C: Avoid use. |
| Pediatric use | Children weighing ≥50 kg: Same as adult; <50 kg: 7.5-10 mg/kg per dose every 6-8 hours, maximum 30 mg/kg/day. |
| Geriatric use | Start at lowest effective dose (200 mg every 6-8 hours), monitor renal function and gastrointestinal bleeding risk; maximum 600 mg/day. |
| 1st trimester | Avoid; associated with increased risk of miscarriage and congenital malformations; use only if clearly needed. |
| 2nd trimester | Use only if clearly needed; may cause oligohydramnios and fetal renal dysfunction. |
| 3rd trimester | Contraindicated; risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for MOTRIN MIGRAINE PAIN (MOTRIN MIGRAINE PAIN).
| Placental transfer | Ibuprofen crosses the placenta; fetal serum concentrations reach about 1-2% of maternal levels. |
| Breastfeeding | Ibuprofen is excreted into breast milk in low amounts (0.6-0.9% of maternal dose); considered compatible with breastfeeding. Use lowest effective dose for shortest duration. |
■ FDA Black Box Warning
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time without warning symptoms. Elderly patients and those with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
| Serious Effects |
Severe hypersensitivity to ibuprofen or NSAIDsHistory of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDsPerioperative pain in the setting of coronary artery bypass graft (CABG) surgeryActive peptic ulcer disease or gastrointestinal bleeding
| Precautions | Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke; risk of serious GI adverse events; avoid in setting of coronary artery bypass graft (CABG) surgery; renal toxicity; anaphylactoid reactions; severe skin reactions (e.g., Stevens-Johnson syndrome); may blunt the antihypertensive effect of ACE inhibitors; avoid late pregnancy due to risk of premature closure of ductus arteriosus. |
| Food/Dietary |
Loading safety data…
| Lactation Rating |
| L1 (Compatible) |
| Teratogenic Risk | First trimester: Risk of spontaneous abortion and congenital malformations (cardiac, gastroschisis). Second trimester: Avoid due to possible oligohydramnios and fetal renal impairment. Third trimester: Contraindicated after 30 weeks gestation due to risk of premature closure of ductus arteriosus and persistent pulmonary hypertension. NSAID use after 20 weeks may cause oligohydramnios from fetal renal dysfunction. |
| Fetal Monitoring | Monitor maternal renal function, blood pressure, and signs of bleeding. Fetal ultrasound to assess amniotic fluid volume if used for >48 hours after 20 weeks gestation. Doppler assessment of ductus arteriosus if used after 30 weeks. |
| Fertility Effects | Reversible inhibition of prostaglandin synthesis may impair ovulation and implantation. Use may delay conception; effects resolve upon discontinuation. Consider in women with unexplained infertility. |
| Avoid alcohol and caffeine-containing foods/drinks (coffee, tea, cola, chocolate) due to additive caffeine effects. Grapefruit juice may increase ibuprofen absorption; consider avoidance. No other significant dietary restrictions. |
| Clinical Pearls | Motrin Migraine Pain contains ibuprofen 200 mg and caffeine 65 mg per tablet. Caffeine enhances analgesic effect and may help with migraine-associated fatigue. Absorb more rapidly on empty stomach; take at first sign of migraine. Avoid in patients with aspirin allergy, peptic ulcer disease, or uncontrolled hypertension. |
| Patient Advice | Take with food or milk if stomach upset occurs. · Do not exceed 2 tablets in 24 hours unless directed by a doctor. · Avoid other caffeine-containing products while taking this medication. · Seek medical attention if migraine is severe or accompanied by stiff neck, speech changes, or vision loss. · Do not use for more than 10 days for headache or 3 days for fever. · Discontinue and contact doctor if rash, swelling, or breathing difficulty occurs. |